Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33,716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study.
Zhou R, Liu F, Zhang H, Wang D, Zhang P, Zheng S, Liu Y, Chen L, Guo J, Zou Y, Rong YM, Liu H, Qiu B. Zhou R, et al. Among authors: liu y, liu h, liu f. Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600. Online ahead of print. Clin Cancer Res. 2024. PMID: 38652815
Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049).
Zhou R, Qiu B, Xiong M, Liu Y, Peng K, Luo Y, Wang D, Liu F, Chen N, Guo J, Zhang J, Huang X, Rong Y, Liu H. Zhou R, et al. Among authors: liu y, liu h, liu f. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):387-399. doi: 10.1016/j.ijrobp.2023.04.021. Epub 2023 Apr 25. Int J Radiat Oncol Biol Phys. 2023. PMID: 37100160 Clinical Trial.
Evaluation of the efficacy and feasibility of concurrent weekly docetaxel-nedaplatin and hypo-fractionated radiotherapy in atypical histologic subtypes of primary and metastatic mediastinal malignancies.
Meng F, Ai X, Wang B, Zhou Y, Li S, Wang D, Liu F, Chen N, Zhou R, Guo J, Huang X, Yin S, Qiu B, Liu H. Meng F, et al. Among authors: liu h, liu f. Front Oncol. 2022 Oct 7;12:974394. doi: 10.3389/fonc.2022.974394. eCollection 2022. Front Oncol. 2022. PMID: 36276120 Free PMC article.
Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients.
Wang D, Qiu B, Liu Q, Xia L, Liu S, Zheng C, Liu H, Mo Y, Zhang X, Hu Y, Zheng S, Zhou Y, Fu J, Chen N, Liu F, Zhou R, Guo J, Fan W, Liu H. Wang D, et al. Among authors: liu h, liu s, liu q, liu f. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3400-3413. doi: 10.1007/s00259-023-06298-x. Epub 2023 Jun 13. Eur J Nucl Med Mol Imaging. 2023. PMID: 37310427
Efficacy and cost-effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059).
Ai X, Zhang P, Xie X, Qiu B, Zhu Y, Zhao L, Xi M, Wu Y, Guo S, Guo J, Liu F, Wang D, Chen N, He Q, Hu Y, Liu M, Ding Z, Liu H. Ai X, et al. Among authors: liu h, liu m, liu f. Cancer Med. 2023 Jul;12(14):15000-15010. doi: 10.1002/cam4.6136. Epub 2023 Jun 16. Cancer Med. 2023. PMID: 37326436 Free PMC article. Clinical Trial.
33,716 results
You have reached the last available page of results. Please see the User Guide for more information.